FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2160793192> ?p ?o ?g. }

• W2160793192 endingPage "23" @default.
• W2160793192 startingPage "17" @default.
• W2160793192 abstract "The aim of the study was to investigate the effects of 1-yr treatment with octreotide (OCT) on left ventricular diastolic and systolic function, assessed at rest and during physical exercise by gated blood pool cardiac scintigraphy, in 30 patients with active acromegaly. OCT was initially given at a dose of 0.05-0.1 mg, 3 times daily, and the dose was subsequently increased to achieve GH/insulin-like growth factor I (IGF-I) normalization. Hormone normalization after treatment was considered when basal and/or oral glucose test-suppressed GH values were below 2.5 and 1 microg/L, respectively, and IGF-I values were within the normal range for age. To evaluate the response to OCT treatment in terms of cardiac performance, the 30 patients were divided into 2 groups on the basis of normalized (in 13 patients) or nonnormalized (in 17 patients) circulating GH and IGF-I levels. At study entry, hypertension was found in 6 patients (20%), abnormal left ventricular diastolic filling was found in 12 patients (40%), and impaired left ventricular ejection fraction was found in 2 patients at rest (6.6%) and in 18 patients at peak exercise (60%). Before OCT treatment, exercise duration ranged from 6-10 min, and exercise workload ranged from 50-125 watts. After 1-yr treatment with OCT, a significant decrease in circulating GH and IGF-I levels was achieved in all patients, but normalization was obtained only in 13 of 30 patients. In patients achieving circulating GH and IGF-I normalization after OCT treatment but not in those with persistently elevated hormone levels, a significant decrease in heart rate, both at rest (from 75.7 +/- 3.3 to 66.5 +/- 2.9 beats/min; P < 0.01) and after exercise (from 137.5 +/- 4.9 to 123.7 +/- 4.1 beats/min; P < 0.01), and a significant increase in left ventricular ejection fraction, both at rest (from 56.5 +/- 1.8% to 66.5 +/- 2.2%; P < 0.01) and after exercise (from 52.6 +/- 2.4% to 67.1 +/- 1.7%; P < 0.01), were found. In the 17 patients who had persistently high circulating GH and IGF-I levels after 1 yr of OCT treatment, left ventricular ejection fraction was unchanged at rest but was significantly reduced after exercise compared to the basal value (from 64.9 +/- 2.4% to 57.2 +/- 2.6%, P < 0.01); systolic blood pressure at rest was significantly increased (from 128.5 +/- 4.9 to 141.2 +/- 5.4 mm Hg; P < 0.05). In these 17 patients, the ejection fraction response to exercise was significantly impaired, mostly in those less than 40 yr of age (from 11.6 +/- 3.2% to -0.3 +/- 5.6%; P < 0.05). In particular, among 9 patients who had a normal response to exercise at study entry, 6 developed an abnormal response after 1 yr. Left ventricular diastolic filling was unchanged by OCT treatment in all patients. Exercise duration (only in young patients from 7.5 +/- 0.5 to 9.3 +/- 0.7 min; P < 0.05) and exercise workload (in all 13 patients from 80.8 +/- 6.4 to 92.3 +/- 5.9 watts; P < 0.05) were significantly increased in the group of patients with normalized GH and IGF levels, but not in the remaining 17 (from 7.6 +/- 0.4 to 7.5 +/- 0.4 min and from 89.9 +/- 5.5 to 84.4 +/- 4.5 watts, respectively). In conclusion, the results of the present study indicate that suppression of basal or glucose-suppressed GH levels below 2.5 or 1 microg/L, respectively, together with normalization of plasma IGF-I levels for 1 yr are followed by a significant improvement, but not complete normalization, of left ventricular ejection fraction either at rest or at peak exercise without significant changes in diastolic filling. By contrast, the persistence for 1 yr of elevated hormone levels caused a significant increase in systolic blood pressure and impaired cardiac performance. These data suggest that prolonged suppression of circulating GH and IGF-I levels could normalize cardiac performance and probably reverse the poor prognosis for cardiovascular disease in acromegaly." @default.
• W2160793192 created "2016-06-24" @default.
• W2160793192 creator A5003544129 @default.
• W2160793192 creator A5003687592 @default.
• W2160793192 creator A5023443410 @default.
• W2160793192 creator A5026888232 @default.
• W2160793192 creator A5043401504 @default.
• W2160793192 creator A5048037056 @default.
• W2160793192 creator A5074115401 @default.
• W2160793192 creator A5077499862 @default.
• W2160793192 date "1999-01-01" @default.
• W2160793192 modified "2023-10-15" @default.
• W2160793192 title "Effects of 1-Year Treatment with Octreotide on Cardiac Performance in Patients with Acromegaly" @default.
• W2160793192 cites W1992000752 @default.
• W2160793192 cites W1995026946 @default.
• W2160793192 cites W2018033127 @default.
• W2160793192 cites W2018786551 @default.
• W2160793192 cites W2043750439 @default.
• W2160793192 cites W2045023284 @default.
• W2160793192 cites W2050574766 @default.
• W2160793192 cites W2050630499 @default.
• W2160793192 cites W2052597101 @default.
• W2160793192 cites W2064092633 @default.
• W2160793192 cites W2066485992 @default.
• W2160793192 cites W2067794530 @default.
• W2160793192 cites W2070446233 @default.
• W2160793192 cites W2081420411 @default.
• W2160793192 cites W2086169986 @default.
• W2160793192 cites W2087826113 @default.
• W2160793192 cites W2088031764 @default.
• W2160793192 cites W2088040716 @default.
• W2160793192 cites W2088209387 @default.
• W2160793192 cites W2099948919 @default.
• W2160793192 cites W2128393448 @default.
• W2160793192 cites W2134282876 @default.
• W2160793192 cites W2176813399 @default.
• W2160793192 cites W2188715846 @default.
• W2160793192 cites W2402220914 @default.
• W2160793192 cites W2402914104 @default.
• W2160793192 cites W2467667708 @default.
• W2160793192 cites W2463711073 @default.
• W2160793192 doi "https://doi.org/10.1210/jcem.84.1.5368" @default.
• W2160793192 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9920056" @default.
• W2160793192 hasPublicationYear "1999" @default.
• W2160793192 type Work @default.
• W2160793192 sameAs 2160793192 @default.
• W2160793192 citedByCount "100" @default.
• W2160793192 countsByYear W21607931922012 @default.
• W2160793192 countsByYear W21607931922013 @default.
• W2160793192 countsByYear W21607931922014 @default.
• W2160793192 countsByYear W21607931922015 @default.
• W2160793192 countsByYear W21607931922016 @default.
• W2160793192 countsByYear W21607931922017 @default.
• W2160793192 countsByYear W21607931922018 @default.
• W2160793192 countsByYear W21607931922019 @default.
• W2160793192 countsByYear W21607931922020 @default.
• W2160793192 countsByYear W21607931922021 @default.
• W2160793192 crossrefType "journal-article" @default.
• W2160793192 hasAuthorship W2160793192A5003544129 @default.
• W2160793192 hasAuthorship W2160793192A5003687592 @default.
• W2160793192 hasAuthorship W2160793192A5023443410 @default.
• W2160793192 hasAuthorship W2160793192A5026888232 @default.
• W2160793192 hasAuthorship W2160793192A5043401504 @default.
• W2160793192 hasAuthorship W2160793192A5048037056 @default.
• W2160793192 hasAuthorship W2160793192A5074115401 @default.
• W2160793192 hasAuthorship W2160793192A5077499862 @default.
• W2160793192 hasBestOaLocation W21607931921 @default.
• W2160793192 hasConcept C111566952 @default.
• W2160793192 hasConcept C126322002 @default.
• W2160793192 hasConcept C134018914 @default.
• W2160793192 hasConcept C164705383 @default.
• W2160793192 hasConcept C2776297358 @default.
• W2160793192 hasConcept C2777433750 @default.
• W2160793192 hasConcept C2778024521 @default.
• W2160793192 hasConcept C2778198053 @default.
• W2160793192 hasConcept C2779306644 @default.
• W2160793192 hasConcept C2779902710 @default.
• W2160793192 hasConcept C2781025020 @default.
• W2160793192 hasConcept C2984496839 @default.
• W2160793192 hasConcept C57900726 @default.
• W2160793192 hasConcept C71315377 @default.
• W2160793192 hasConcept C71924100 @default.
• W2160793192 hasConcept C78085059 @default.
• W2160793192 hasConcept C84393581 @default.
• W2160793192 hasConceptScore W2160793192C111566952 @default.
• W2160793192 hasConceptScore W2160793192C126322002 @default.
• W2160793192 hasConceptScore W2160793192C134018914 @default.
• W2160793192 hasConceptScore W2160793192C164705383 @default.
• W2160793192 hasConceptScore W2160793192C2776297358 @default.
• W2160793192 hasConceptScore W2160793192C2777433750 @default.
• W2160793192 hasConceptScore W2160793192C2778024521 @default.
• W2160793192 hasConceptScore W2160793192C2778198053 @default.
• W2160793192 hasConceptScore W2160793192C2779306644 @default.
• W2160793192 hasConceptScore W2160793192C2779902710 @default.
• W2160793192 hasConceptScore W2160793192C2781025020 @default.
• W2160793192 hasConceptScore W2160793192C2984496839 @default.
• W2160793192 hasConceptScore W2160793192C57900726 @default.
• W2160793192 hasConceptScore W2160793192C71315377 @default.

• next